English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
NEWS
Press Release
Media Report
Year:
Select
2024
2020
2019
2018
2017
Media Report
28
May 2024
PharmaBoardroom
HKEX-main board listed Alphamab Oncology is one of China's leading biotech success stories, having developed and marketed the world's first subcutaneously injectable PD-L1 inhibitor
14
June 2020
ENDPOINTS NEWS
Sanofi sharpens focus on bispecifics, and China, with Alphamab deal
14
June 2020
ENDPOINTS NEWS
Two years in, Hong Kong's biotech experiment has been validated
14
May 2020
PharmaBoardroom
Alphamab Oncology is Committed to Developing Portfolio and Generating Value for Stakeholders
13
December 2019
BIOWORLD
Bispecific antibody specialist Alphamab raises $234M on HKEX
13
December 2019
ENDPOINTS NEWS
Alphamab Oncology rounds out HKEX's second biotech IPO year with $230M raise and high local interest
12
December 2019
BIOCENTURY
Local demand high for Alphamab Oncology’s Hong Kong IPO
04
December 2019
BIOCENTURY
Alphamab Oncology sets sights on $220M IPO as HKSE continues to gain momentum
27
December 2019
BIOWORLD
Alphamab hauls in $60M series B, eyes HKEX listing to advance bispecific platform
30
May 2019
ENDPOINTS NEWS
Ready to harvest its PD-L1, Alphamab reloads with $60M to nurture the bispecific patch
1
2
PREV
1/2
NEXT